Drug intelligence / Profile preview

RGB-14-P

Development stage: Unknown
Lead developer: Gedeon Richter
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

RGB-14-P is a biosimilar of denosumab (Prolia®) being developed by Gedeon Richter for the treatment of osteoporosis and other bone-related conditions. It is a human monoclonal antibody that inhibits RANK ligand, which helps slow down bone breakdown. The drug is administered as a subcutaneous injection and is being developed as a biosimilar to both Prolia® and Xgeva® reference products.

Other names: denosumab biosimilar

Targets

RANKL (Receptor Activator for Nuclear Factor-kappa B Ligand)

Beyond the preview

Go deeper on RGB-14-P.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RGB-14-P.

Explore the full profile